-
公开(公告)号：US09403844B2
公开(公告)日：2016-08-02
申请号：US14733786
申请日：2015-06-08
申请人： Dharmaraj Ramachandra Rao , Rajendra Narayanrao Kankan , Manjinder Singh Phull , Maruti Ghagare
发明人： Dharmaraj Ramachandra Rao , Rajendra Narayanrao Kankan , Manjinder Singh Phull , Maruti Ghagare
IPC分类号： C07D498/22
CPC分类号： A61K31/437 , C07D498/22
摘要： Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
-
公开(公告)号：US20160031905A1
公开(公告)日：2016-02-04
申请号：US14777495
申请日：2014-03-14
发明人： Jan HOFLACK , Petra BLOM , Olivier LAVERGNE
IPC分类号： C07D498/18 , C07D498/22 , C07D487/18
CPC分类号： C07D498/18 , C07D487/18 , C07D498/22
摘要： The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 kinase, for use in the diagnosis, prevention and/or treatment of LRRK2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent. Finally, the present invention also relates to new macrocyclic compounds.
摘要翻译： 本发明涉及大环化合物和含有作为激酶抑制剂的化合物，特别是作为LRRK2激酶抑制剂的组合物，用于诊断，预防和/或治疗LRRK2激酶相关疾病。 此外，本发明提供使用所述化合物的方法，例如作为药物或诊断剂。 最后，本发明还涉及新的大环化合物。
-
公开(公告)号：US20160002263A1
公开(公告)日：2016-01-07
申请号：US14769646
申请日：2014-03-10
发明人： B. NARASIMHULU NAIDU , MANOJ PATEL , KEVIN PEESE
IPC分类号： C07D498/22 , A61K45/06 , A61K31/529 , C07D515/22
CPC分类号： C07D498/22 , A61K31/529 , A61K45/06 , C07D487/04 , C07D498/18 , C07D513/22 , C07D515/22
摘要： The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. Formule (I)
摘要翻译： 本公开一般涉及式I化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。 本公开提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。 Formule（I）
-
公开(公告)号：US20150368267A1
公开(公告)日：2015-12-24
申请号：US14765910
申请日：2014-02-04
发明人： Tao WANG , Zhongxing ZHANG , Zhiwei YIN , Li-Qiang SUN , Eric MULL , Qian ZHAO , Paul Michael SCOLA
IPC分类号： C07D498/22 , A61K31/53 , C07D498/20 , A61K31/551 , C07D498/08 , A61K45/06 , C07D498/18
CPC分类号： C07D498/22 , A61K31/53 , A61K31/551 , A61K45/06 , C07D498/08 , C07D498/18 , C07D498/20
摘要： Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
摘要翻译： 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
公开(公告)号：US09193740B2
公开(公告)日：2015-11-24
申请号：US12907614
申请日：2010-10-19
申请人： Yonghua Gai , Yat Sun Or , Guoqiang Wang
发明人： Yonghua Gai , Yat Sun Or , Guoqiang Wang
IPC分类号： C07D498/22 , A61K38/12 , A61K38/21 , A61P31/14 , A61K31/495 , A61K45/06
CPC分类号： C07D498/22 , A61K31/495 , A61K45/06
摘要： The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明公开了式Ia或Ib的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US09193727B2
公开(公告)日：2015-11-24
申请号：US13414657
申请日：2012-03-07
申请人： Pavel Khokhlov , Pavel Ivan Lazarev , Alexey Nokel
发明人： Pavel Khokhlov , Pavel Ivan Lazarev , Alexey Nokel
IPC分类号： C07D471/06 , C07D241/46 , C07D495/14 , C07D498/22 , H01L51/46 , H01L31/0224 , C07D471/22 , C07D487/16 , C07D493/06 , C07D498/04 , C07D513/14 , C07D519/00 , H01L51/00 , H01L51/42
CPC分类号： H01L51/0072 , C07D241/46 , C07D471/06 , C07D471/22 , C07D487/16 , C07D493/06 , C07D495/14 , C07D498/04 , C07D498/22 , C07D513/14 , C07D519/00 , C09B5/62 , H01L51/0053 , H01L51/0055 , H01L51/0058 , H01L51/0071 , H01L51/42 , Y02E10/549
摘要： The present invention provides a organic compound of the general structural formula I and photovoltaic device and photovoltaic layer comprising thereof Said organic compound forms rod-like supramolecules and absorbs electromagnetic radiation in at least one predetermined spectral subrange within a wavelength range from 400 to 3000 nm with excitation of electron-hole pairs. The polycyclic core Cor1, the bridging group B, and the polycyclic core Cor2 form a molecular system selected from the list comprising donor-bridge-acceptor-bridge-donor and acceptor-bridge-donor-bridge-acceptor in which a dissociation of excited electron-hole pairs is carried out. A solution of the organic compound or its salt forms a solid photovoltaic layer on a substrate.
摘要翻译： 本发明提供一般结构式I的有机化合物和包含它的光伏器件和光伏层。所述有机化合物形成棒状超分子，并且在400至3000nm的波长范围内的至少一个预定光谱子范围内吸收电磁辐射， 激发电子 - 空穴对。 多环核心Cor1，桥连基团B和多环核心Cor2形成选自包括供体 - 桥 - 受体 - 桥 - 供体和受体 - 桥 - 供体 - 桥 - 受体的列表的分子系统，其中激发电子 进行了孔对。 有机化合物或其盐的溶液在基材上形成固体光伏层。
-
公开(公告)号：US09187495B2
公开(公告)日：2015-11-17
申请号：US14515684
申请日：2014-10-16
IPC分类号： C07D498/22
CPC分类号： A61K31/5383 , C07D498/22
摘要： Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.
摘要翻译： 公开了式（I）化合物，其药学上可接受的盐，以及式（I）化合物用于治疗细菌感染的用途。
-
公开(公告)号：US20150266898A1
公开(公告)日：2015-09-24
申请号：US14733786
申请日：2015-06-08
IPC分类号： C07D498/22
CPC分类号： A61K31/437 , C07D498/22
摘要： Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
-
公开(公告)号：US20150266897A1
公开(公告)日：2015-09-24
申请号：US14638733
申请日：2015-04-03
发明人： Nigel J. Liverton , Vincenzo Summa , Maria Emilia Di Francesco , Marco Ferrara , Kevin F. Gilbert , Steven Harper , John A. McCauley , Charles J. McIntyre , Alessia Petrocchi , Marco Pompei , Joseph J. Romano , Michael T. Rudd , John W. Butcher , M. Katharine Holloway
IPC分类号： C07D498/22 , A61K31/437 , A61K31/439 , C07D498/08 , A61K31/407 , A61K31/4192 , C07D498/18 , A61K45/06
CPC分类号： C07D498/22 , A61K31/407 , A61K31/4192 , A61K31/437 , A61K31/439 , A61K38/00 , A61K45/06 , C07D498/08 , C07D498/18 , C07K5/0804 , C07K5/0806 , C07K5/0808 , C07K5/0812
摘要： The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
摘要翻译： 本发明涉及可用作丙型肝炎病毒（HCV）NS3蛋白酶抑制剂及其合成及其用于治疗或预防HCV感染的用途的式（I）的大环化合物。
-
公开(公告)号：US09133217B2
公开(公告)日：2015-09-15
申请号：US14288184
申请日：2014-05-27
申请人： Stephan D. Parent , Lisa Lynn McQueen , Patricia Andres , Paul Schields , Yiduo Wu , Fei Ding , Jared Peters Smit
发明人： Stephan D. Parent , Lisa Lynn McQueen , Patricia Andres , Paul Schields , Yiduo Wu , Fei Ding , Jared Peters Smit
IPC分类号： C07D498/12 , C07D498/22
CPC分类号： C07D491/22 , A61K31/4184 , A61K31/439 , C07B2200/13 , C07D498/18 , C07D498/22 , Y02A50/473
摘要： Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
摘要翻译： 实施方案涉及利福昔明多晶型物，盐和水合物形式，多形态形式的制备方法及其在药物制剂中的应用以及使用它们的治疗方法。
-
-
-
-
-
-
-
-
-
搜索结果
1001 条记录 (耗时 0.051 秒)
